SAR, QSAR and docking of anticancer flavonoids and variants: A review

Current Topics in Medicinal Chemistry

Volumn 12, Issue 24, 2012, Pages 2785-2809

  Scotti, Luciana ^a   Mendonça, Francisco Jaime Bezerra ^b   Moreira, Diogo Rodrigo Magalhaes ^c   Da Silva, Marcelo Sobral ^a   Pitta, Ivan R ^d   Scotti, Marcus Tullius ^a  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^b STATE UNIVERSITY OF PARAÍBA   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Cancer; Descriptors; Docking; Flavonoids; QSAR; SAR

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; CYTOCHROME P450; FLAVONOID; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN; KAEMPFEROL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; QUERCETIN; RAF PROTEIN; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOLOGICAL ACTIVITY; BREAST CARCINOMA; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DRUG SCREENING; ESTROGEN SYNTHESIS; HUMAN; MOLECULAR DOCKING; MULTIPLE LINEAR REGRESSION ANALYSIS; OXIDATIVE STRESS; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RANDOM FOREST; SKIN CANCER; STRUCTURE ACTIVITY RELATION; ALGORITHM; BINDING SITE; CHEMISTRY; DRUG DEVELOPMENT; NEOPLASM; PROTEIN BINDING; REVIEW; THERMODYNAMICS;

ALGORITHMS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; DRUG DISCOVERY; FLAVONOIDS; HUMANS; MOLECULAR DOCKING SIMULATION; NEOPLASMS; NEURAL NETWORKS (COMPUTER); PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 84883237081     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212240007     Document Type: Article

References (136)

1. Pannala, A.S.; Chan, S.T.; O’Brien J.P.; Rice-Evans A.C. Flavon-oid B-ring chemistry and antioxidant activity: fast reaction kinetics.Biochem. Biophys. Res. Commun., 2001, 282, 1161-1168.
2. Rolim, A.; Oishi, T.; Maciel, C.P.M.; Zague, V.; Pinto, C.A.S.O.; Kaneko, T.M.; Consiglieri, V.O.; Velasco, M.V.R. Total flavonoidsquantification from O/W emulsion with extract of Brazilian plants, Int. J. Pharm., 2006, 308, 107-114.
3. Vaya, J.; Mahemood, S.; Goldblum, A.; Aviram, M.; Volkova, N.; Shaalan, A.; Musa, R.; Tamir, S. Inhibition of LDL oxidation byflavonoids in relation to their structure and calculated en-thalpy.Phytochem., 2003, 62, 89-99.
4. Cardoso, C.L.; Silva, D.H.S.; Castro-Gamboa, I.; Bolzani, V.S. New biflavonoid and other flavonoids from the leaves of Chimar-rhis turbinata and their antioxidant activities, J. Braz. Chem. Soc.,2005, 16, 1353-1359.
5. Farkas, O.; Jakus, J.; Héberger, K. Quantitative structure -antioxidant activity relationships of flavonoid compounds. Molecules, 2004, 9, 1079-1088.
6. Hyun, J.; Shin, S.Y.; So K.M.; Lee Y.H.; Lim Y. Isoflavones in-hibit the clonogenicity of human colon cancer cells. Bioorg. Med.Chem. Lett., 2012, 22, 2664-2669.
7. Shin, S.Y.; Woo, Y.; Hyun, Y.; Dongsoo, K.; Lee, Y.H.; Lim, Y. Relationship between the structures of flavonoids and their NF- B-dependent transcriptional activities. Bioorg. Med. Chem. Letters,2011, 21, 6036-6041.
8. Ou, L.; Han, S.; Ding, W.; Chen, Z.; Ye, Z.; Yang, H.; Zhang, G.; Lou, Y.; Chen, J.-Z.; Yu, Y. Design, synthesis and 3D-QSAR studyof cytotoxic flavonoid derivatives. Mol. Divers., 2011, 15, 665-675.
9. Weng, C.J.; Yen, G.-C. Chemopreventive effects of dietary phyto-chemicals against cancer invasion and metastasis: Phenolic acids,monophenol, polyphenol, and their derivatives. Cancer Treat. Rev.,2012, 38, 76-87.
10. Todeschini, R.; Consonni, V. Molecular Descriptors for Chemoin-formatics, WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim,2009.
11. Scotti, L.; Velasco, M.V.R. Envelhecimento cutâneo à luz da Cos-metologia, Tecnopress: São Paulo, 2003.
12. Scotti, L.; Scotti, M.T.; Pasqualoto, K.F.M.; Bolzani, V.S. Molecular physicochemical parameters predicting antioxidant activity ofBrazilian natural products. Braz. J. Pharmacogn., 2009, 19, 908-913.
13. Scotti, L.; Scotti, M.T.; Cardoso, C.L.; Pauletti, P.M.; Gamboa, I.C.; Bolzani, V.S.; Velasco, M.V.R.; Menezes, C.M.S.; Ferreira, E.I. Modelagem molecular aplicada ao desenvolvimento de molé-culas com atividade antioxidante visando ao uso cosmético. Rev.Bras. Cienc. Farm., 2007, 43, 153-166.
14. Cheng, Z.; Ren, J.; Yan, G.; Li, Y.; Chang, W.; Chen, Z. Quantitative elucidation of the molecular mechanisms of hydroxyl radicalquenching reactivity of phenolic compounds. Bioorg. Chem., 2003,31, 149-162.
15. Zhang, Y. Theoretical methods used in elucidating activity differ-ences of phenolic antioxidants, J. Am. Oil Chem. Soc., 1999, 76,745-748.
16. Cao, H.; Cheng, W.X.; Li, C.; Pan, X.L.; Xie, X.G., Li, T.H. DFTstudy on the antioxidant activity of rosmarinic acid, J. Mol. Struct.(Theochem), 2005, 719, 177-183.
17. Zhang, S.; Yang, X.; Coburn, R.A.; Morris, M.E. Structure activityrelationships and quantitative structure activity relationships for theflavonoid-mediated inhibition of breast cancer resistance protein. Biochem. Pharmacol., 2005, 70, 627-639.
18. Gandhi, Y.A.; Morris, M.E. Structure-activity relationships andquantitative structure-activity relationships for breast cancer resistance protein (ABCG2). AAPS J., 2009, 11, 541-552.
19. Xie, Y.; Linn, D. E.; Yang, X.; Guo, Z.; Shimelis, H.; Nakanishi, T.; Ross, D. D.; Chen, H.; Fazli, L.; Gleave, M. E.; Qiu, Y. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby pro-motes its multimerization and drug-resistant activity in humanprostate cancer cells. J. Bio. Chem., 2008, 283, 3349-3356.
20. Pick, A.; Müller, H.; Mayer, R.; Haenisch, B.; Pajeva, I.K.; Weigt, M.; Bönisch, H.; Müller, C.E.; Wiese, M. Structure-activity rela-tionships of flavonoids as inhibitors of breast cancer resistance pro-tein (BCRP). Bioorg. Med. Chem., 2011, 19, 2090-2102.
21. Cheng, Z.; Ren, J.; Li, Y.; Chang, W.; Chen, Z. Study on the multi-ple mechanisms underlying the reaction between hydroxyl radicaland phenolic compounds by qualitative structure and activity rela-tionship. Bioorg. Med. Chem., 2002, 10, 4067-1073.
22. Saija, A.; Tomaino, A.; Trombetta, D.; Pasquale, A.D.; Uccella, N.; Barbuzzi, T.; Paolino, D.; Bonina, F. In vitro and in vivo evaluationof caffeic and ferulic acids as topical photoprotective agents, Int. J.Pharm., 2000, 199, 39-47.
23. Ghose, A.K.; Pritchett, A.; Crippen, G.M. Atomic physicochemicalparameters of three dimensional structure directed quantitativestructure-activity relationships III: Modeling hydrophobic interactions. J. Comput. Chem., 1988, 9, 80-90.
24. Speck-Planche, A.; Kleandrova, V.V.; Luan F.; Cordeiro, M.N.D.S. Chemoinformatics in multi-target drug discovery for anti-cancertherapy: in silico design of potent and versatile anti-brain tumoragents. Anti-Cancer Agent. Med. Chem., 2012, 12, 678-685.
25. Speck-Planche, A.; Kleandrova, V.V.; Luan F.; M.N.D.S. Cordeiro. Rational drug design for anti-cancer chemotherapy: Multi-targetQSAR models for the in silico discovery of anti-colorectal canceragents. Bioorg. Med. Chem., 2012, 20, 4848-4855.
26. Speck-Planche, A.; Kleandrova, V.V.; Luan F.; M.N.D.S. Cordeiro. Chemoinformatics in anti-cancer chemotherapy: Multi-targetQSAR model for the in silico discovery of anti-breast canceragents. Eur. J. Pharm. Sci., 2012, 47, 273-279.
27. Scotti, M.T.; Fernandes, M.B.; Ferreira, M.J.P.; Emereciano, V.P.; Quantitative structure-activity relationship of sesquiterpene lac-tones with cytotoxic activity. Bioorg. Med. Chem., 2007, 15, 2927-2934.
28. Aguiar-Pulido V.; Munteanu, C.R.; Seoane, J.A.; Fernández-Blanco E.; Pérez-Montoto L.G.; González-Díaz H.; Dorado, J.; Na-ïve Bayes QSDR classification based on spiral-graph Shannon en-tropies for protein biomarkers in human colon cancer. Mol. Bio-Syst., 2012, 8, 1716-1722.
29. Martínez-Romero, M.; Vázquez-Naya, J.M.; Rabuñal, J.R.; Pita-Fernández, S.; Macenlle, R.; Castro-Alvariño, J.; López-Roses, L.; Ulla, J.L.; Martínez-Calvo, A.V.; Vázquez, S.; Pereira, J.; Porto-Pazos, A.B; Dorado, J.; Pazos, A.; Munteanu, C.R. Artificial intelligence techniques for colorectal cancer drug metabolism: ontolo-gies and complex networks. Curr. Drug Metab., 2010, 11, 347-368.
30. Munteanu C.R.; Magalhães A.L.; Uriarte E.; González-Díaz H.; Multi-target QPDR classification model for human breast and co-lon cancer-related proteins using star graph topological indices. J.Theor. Biol., 2009, 257, 303-311.
31. Fernández-Blanco E.; Aguiar-Pulido V.; Munteanu, C.R.; Dorado, J.; Random Forest classification basedon star graph topological in-dices for antioxidant proteins. J. Theor. Biol., 2013, 317, 331-337.
32. Burda, S.; Oleszek, W. Antioxidant and antiradical activities offlavonoids. J. Agric. Food Chem., 2001, 49, 2774-2779.
33. Bandgar, B.P.; Gawande, S.S.; Bodade, R.G.; Totre, J.V.; Khobra-gade, C.N. Synthesis and biological evaluation of simple methoxy-lated chalcones as anticancer, anti-inflammatory and antioxidantagents. Bioorg. Med. Chem., 2010, 18, 1364-1370.
34. Reddy, M.V.B.; Shen, Y.C.; Ohkoshi, E.; Bastow, K.F.; Qian, K.; Lee, K.-H.; Wu, T.S. Bis-chalcone analogues as potent NO produc-tion inhibitors and as cytotoxic agents. Eur. J. Med. Chem., 2012,47, 97-103.
35. Kothandan, G.; Gadhe, C.G.; Madvhan, T.; Choi, C.H.; Cho, S.J. Docking and 3D-QSAR (quantitative structure activity relation-ship) studies of flavones, the potent inhibitors of p-glycoproteintargeting the nucleotide binding domain. Eur. J. Med. Chem., 2011,46, 4078-4088.
36. Boccard, J.; Bajot, F.; Di Pietro, A.; Rudaz, S.; Boumendjel, A.; Nicolle, E.; Carrupt, P.A. A 3D linear solvation energy model toquantify the affinity of flavonoid derivatives towards P-glycoprotein. Eur. J. Pharm. Sci., 2009, 36, 254-264.
37. Holder, S.; Lilly, M.; Brown, M. Comparative molecular fieldanalysis of flavonoid inhibitors of the PIM-1 kinase, Bioorg. Med.Chem., 2007, 15, 6463-6473.
38. Tropsha, A.; Gramatica, P.; Gombar, V.K. The importance of beingearnest: validation is the absolute essential for successful applica-tion and interpretation of QSPR models. QSAR Comb. Sci., 2003,22, 69-77.
39. Höltje, H.D.; Sippl, W.; Rognan, D.; Folkers, G. Molecular Model-ing. Basic Principles and Applications, 3rd ed.; Wiley-VCH: Wein-heim, 2008.
40. Bhattacharjee, A.K.; Kyle, D.E.; Vennrstrom, J.L.; Milhous, W.K.A 3D QSAR Pharmacophore Model and Quantum Chemical Struc-ture-Activity Analysis of Chloroquine(CQ)-Resistance Reversal. J.Chem. Inf. Comput. Sci., 2002, 42, 1212-1220.
41. roda, K.; Michalak, K.; Maniewska J.; Gynkiewicz, G.; Szeja, W.; Szeja, W.; Zawisza, J.; Hendrich, A.B. Genistein derivatives de-crease liposome membrane integrity— Calcein release and molecu-lar modeling study. Biophys. Chem., 2008, 138, 78-82.
42. Seyoum, A.; Asres, K.; El-Fiky, F.K. Structure-radical scavengingactivity relationships of flavonoids. Phytochemistry, 2006, 67,2058-2070.
43. Scotti, L.; Scotti, M.T.; Bolzani, V.S.; Ferreira, E.I. Molecularphysicochemical parameters predicting antioxidant activity of Bra-zilian Natural Products. Rev. Bras. Farmacogn., 2010, 19, 908-913.
44. Singh, R.; Jain, A.; Ravichandran, V.; Mourya, V.; Agrawal, R.K. Prediction of antiproliferative activity of some flavone derivatives:QSAR study. Med. Chem. Res., 2009, 18, 523-537.
45. Wang, T.; Chen, I.L.; Lu, P.J.; Wong, C.H.; Liao, C.H.; Tsiao, K.C.; Chang, K.M.; Chen, Y.L.; Tzeng, C.C. Synthesis, and cyto-toxic and antiplatelet activities of oxime- and methyloxime-containing flavone, isoflavone, and xanthone derivatives. Bioorg.Med. Chem., 2005, 13, 6045-6053.
46. Fassihi, A.; Sabet, R. QSAR Study of p56lck protein tyrosinekinase inhibitory activity of flavonoid derivatives using MLR andGA-PLS. Int. J. Mol. Sci., 2008, 9, 1876-1892.
47. Goodford, P.J. A computational procedure for determining ener-getically favorable binding sites on biologically important macro-molecules. J. Med. Chem., 1985, 28, 849-857.
48. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative MolecularField Analysis (CoMFA). 1. Effect of Shape on Binding of Steroidsto Carrier Proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
49. Nicolle, E.; Boccard, J.; Guilet, D.; Dijoux-Franca, M.G.; Zelefac, F.; Macalou, S.; Grosselin, J.; Schmidt, J.; Carrupt, P.-A.; Pietro, A.D.; Boumendjel, A. Breast cancer resistance protein(BCRP/ABCG2): New inhibitors and QSAR studies by a 3D linearsolvation energy approach. Eur. J. Pharm. Sci., 2009, 38, 39-46.
50. Cruciani, G.; Crivori, P.; Carrupt, P.A.; Testa, B. Molecular fieldsin quantitative structure permeation relationships: the VolSurf ap-proach. J. Mol. Struct.-Theochem, 2000, 503, 17-30.
51. Scotti, L.; Fernandes, M.B.; Maramatsu, E.; Pasqualoto, K.F.M.; Emerenciano, V.P.; Tavares, L.C.; Silva, M.S.; Scotti, M.T. Self-organizing maps and VolSurf approach to predict aldose reductaseinhibition by flavonoid compounds. Rev. Bras. Farmacogn., 2011,21, 170-180.
52. Pietro, A.D.; Conseil, G.; Perez-Victoria, J.M.; Dayan, G.; Baubichon-Cortay, H.; Trompier, D.; Stein-Fels, E.; Jault, J.M.; DeWet, H.; Maitrejean, M.; Comte, G.; Boumendjel, A.; Mariotte, A.M.; Dumontet, C.; McIntosh, D.B.; Goffeau, A.; Castanys, S.; Gamarro, F.; Barron, D. Modulation by flavonoids of cellmultidrug resistance mediated by P-glycoprotein and related ABCtransporters. Cell. Mol. Life Sci., 2002, 59, 307-322.
53. Cheng, Z.J.; Zhang, Y.T.; Fu, W.Z. QSAR study of carboxylic acidderivatives as HIV-1 integrase inhibitors, Eur. J. Med. Chem.,2010, 45, 3970-3980.
54. Wang, Z.Z.; Li, Y.; Ai, C.Z.; Wang, Y.H. In silico prediction ofestrogen receptor subtype binding affinity and selectivity using sta-tistical methods and molecular docking with 2-arylnaphthalenesand 2-arylquinolines. Int. J. Mol. Sci., 2010, 11, 3434-3458.
55. Wang, Y.H.; Li, Y., Yang, S.L.; Yang, L. An in silico approach forscreening flavonoids as P-glycoprotein inhibitors based on a Baye-sian-regularized neural network. J. Comput. Aided Mol. Des., 2005,19, 137-147.
56. Weber, K.C.; Honório, K.M.; Bruni, A.T.; Andricopulo, A.D.; Silva, A.B.F. A partial least squares regression study with antioxi-dant flavonoid compounds. Struct. Chem., 2006, 17, 307-313.
57. Rouer, E.; Expression of the p56lck by colon tumors: a marker oftheir invasive capacity? B. Cancer, 2004, 91, 928-940.
58. Niikolovska-Coleska, Z.; Suturkova, L.; Krbavic, A.; Solmayer, T. Quantitative structure-activity relationship of flavonoid inhibitorsof p56lck protein tyrosine kinase: a classical/quantum chemical ap-proach. Quant. Struct.-Act. Relat., 1998, 17, 7-13.
59. Zhou, Y.P.; Tang, L.J., Jiao, J., Song, D.D.; Jiang, J.H.; Yu, R.Q. Modified particle swarm optimization algorithm for adaptivelyconfiguring globally optimal classification and regression trees, J.Chem. Inf. Model. 2009, 49, 1144-1153.
60. Kubinyi H., 3D QSAR in Drug Design. Theory, Methods and Ap-plications, ESCOM, Science Publishers B.V.: Leiden, 1993.
61. Cassidy, C.E.; Setzer, W.N. Cancer-relevant biochemical targets ofcytotoxic Lonchocarpus flavonoids: A molecular docking analysis.J. Mol. Model., 2010, 16, 311-326.
62. Rodriguez-Antona, C.; Ingelman-Sundberg, M. Cytochrome P450pharmacogenetics and câncer. Oncogene, 2006, 25, 1679-1691.
63. Paoletta, S.; Steventon, G.B.; Wildeboer, D.; Ehrman, T.M.; Hy-lands P.J.; Barlow, D.J. Screening of herbal constituents for aro-matase inhibitory activity. Bioorg. Med. Chem., 2008, 16, 8466-8470
64. Ehrman T.M.; Barlow, D.J.; Hylands, P.J.; Phytochemical data-bases of Chinese herbal constituents and bioactive plant com-pounds with known target specificities. J. Chem. Inf. Model.,2007, 47, 254-263.
65. Gobbi, S.; Cavalli, A.; Bisi, A.; Recanatini, M.; From nonsteroidalaromatase inhibitors to multifunctional drug candidates: classic andinnovative strategies for the treatment of breast cancer. Curr. Top.Med. Chem., 2008, 8, 869-887.
66. Benson, J.R.; Ravisekar, O. Aromatase Inhibitors for Treatment ofBreast Cancer.Curr. Cancer Treat.Rev., 2007, 3, 67-79.
67. Brueggemeier, R.W.; Hackett, J.C.; Diaz-Cruz, E.S. Aromataseinhibitors in the treatment of breast cancer. Endocr. Rev., 2005, 26,331-345.
68. Hall, L.H.; Kier, L.B. The molecular connectivity chi indexes andkappa shape indexes in structure-property modeling. Rev. Comput.Chem., 1991, 2, 367-422.
69. Labute, P.A.J. A widely applicable set of descriptors. Mol. Graph-ics Modell., 2000, 18, 464-477.
70. Favia, A. D.; Cavalli, A.; Masetti, M.; Carotti, A.; Recanatini, M. Three-dimensional model of the human aromatase enzyme anddensity functional parameterization of the iron-containing pro-toporphyrin IX for a molecular dynamics study of heme-cysteinatocytochromes. Proteins Struct.Funct. Bioinform., 2006, 62, 1074-1087.
71. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexibledocking method using an incremental construction algorithm. J.Mol. Biol., 1996, 261, 470-489.
72. Takemura, H.; Itoh, T.; Yamamoto, K.; Sakakibara, H.; Shimoi, K. Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg. Med. Chem., 2010, 18, 6310-6315.
73. Sansen, S.; Yano, J.K.; Reynald, R.L.; Schoch, G.A.; Griffin, K.J.; Stout, C.D.; Johnson, E.F. Adaptations for the oxidation of poly-cyclic aromatic hydrocarbons exhibited by the structure of humanP450 1A2. J. Biol. Chem., 2007, 282, 14348-14355.
74. He, L.; He, F.; Bi, H.; Li, J.; Zeng, S.; Luo, H.; Huang, M. Isoform-selective inhibition of chrysin towards human cytochrome P4501A2. Kinetics analysis, molecular docking, and molecular dynam-ics simulations. Bioorg. Med. Chem. Lett., 2010, 20, 6008-6012.
75. Wu, G.; Robertson, D.H.; Brooks, C.L.; Vieth, M. Detailed analy-sis of grid-based molecular docking: A case study of CDOCKER—A CHARMm-based MD docking algorithm. J. Comput. Chem.,2003, 24, 1549-1562.
76. Shimada, T.; Tanaka, K.; Takenaka, S.; Murayama, N.; Martin, M.V.; Foroozesh, M.K.; Yamazaki, H.; Guengerich, F.P.; Komori, M. Structure-function relationships of inhibition of human cyto-chromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid de-rivatives. Chem. Res. Toxicol., 2010, 23, 1921-1935.
77. Wester, M.R.; Yano, J.K.; Schoch, G.A.; Yang, C.; Griffin, K.J.; Stout, C.D.; Johnson, E.F. The structure of human cytochromeP450 2C9 complexed with flurbiprofen at 2.0-A resolution. J. Biol.Chem., 2004, 279, 35630-35637.
78. Yano, J.K.; Wester, M.R.; Schoch, G.A.; Griffin, K.J.; Stout, C.D.; Johnson, E.F.; The structure of human microsomal cytochromeP450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J. Biol. Chem., 2004, 279, 38091-38094.
79. Androutsopoulos, V.P.; Papakyriakou, A.; Vourloumis, D.; Span-didos, D.A. Comparative CYP1A1 and CYP1B1 substrate and in-hibitor profile of dietary flavonoids. Bioorg. Med. Chem., 2011, 19,2842-2849.
80. Eswar, N.; John, B.; Mirkovic, N.; Fiser, A.; Ilyin, V. A.; Pieper, U.; Stuart, A. C.; Marti-Renom, M. A.; Madhusudhan, M. S.; Yerkovich, B.; Sali, A. Tools for comparative protein structuremodeling and analysis. Nucleic Acids Res., 2003, 31, 3375-3380.
81. Kirchmair, J.; Wolber, G.; Laggner, C.; Langer, T. Comparativeperformance assessment of the conformational model generatorsomega and catalyst: a large-scale survey on the retrieval of protein-bound ligand conformations. J. Chem. Inf. Model., 2006, 46, 1848-1861.
82. Sanner, M. F. Python: A programming language for software inte-gration and development. J. Mol. Graphics Modell., 1999, 17, 57-61.
83. Huey, R.; Morris, G.M.; Olson, A.J.; Goodsell, D.S. A semiempiri-cal free energy force field with charge-based desolvation. J. Com-put. Chem., 2007, 28, 1145-1152.
84. Bonfield, K.; Amato, E.; Bankemper, T.; Agard, H.; Steller, J.; Keeler, J.M.; Roy, D.; McCallum, A; Paula, S.; Ma, L. Development of a new class of aromatase inhibitors: Design, synthesis andinhibitory activity of 3-phenylchroman-4-one (isoflavanone) de-rivatives. Bioorg. Med. Chem., 2012, 20, 2603-2613.
85. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267, 727-748.
86. Narayana, B.L.; Pran Kishore, D.; Balakumar, C.; Rao, K.V; Kaur, R.; Rao, A.R; Murthy, J.N.; Ravikumar, M. Molecular ModelingEvaluation of Non-Steroidal Aromatase Inhibitors. Chem. Biol.Drug. Des., 2012, 79, 674-682.
87. Ghosh, D.; Griswold, J.M.; Pangborn, W. Structural basis for an-drogen specificity and oestrogen synthesis in human aromatase.Nature, 2009, 457, 219-224.
88. Bheemanapalli, L.N.; Kaur, A.; Arora, R.; Sangeeta ; Akkinepally, R.R.; Javali, N.M. Synthesis, evaluation of 6,8-dibromo-2-aryl-2,3-dihydroquinolin-4(1H)-ones in MCF-7 (breast cancer) cell linesand their docking studies. Med. Chem. Res., 2012, 21, 1741-1750.
89. Shchemelinin, I.; Sefc, L.; Necas, E.; Protein kinases, their functionand implication in cancer and other diseases. Folia Biol., 2006, 52,81-100.
90. Lee, K.W.; Kang, N.J.; Heo, Y.; Rogozin, E.A.; Pugliese, A.; Hwang, M. K.; Bowden, G.T.; Bode, A.M.; Lee, H.J.; Raf, Z.D.; MEK pro-tein kinases are direct molecular targets for the chemopreventiveeffect of quercetin, a major flavonol in red wine. Cancer Res.,2008, 68,946-955.
91. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ.Activation of mitogen-activated protein kinase associated withprostate cancer progression. Cancer Res., 1999, 59,279-284.
92. Lee, K.M.; Lee, D.E.; Seo, S.K.; Hwang, M.K.; Heo, Y.; Lee, K.W.; Lee, H.J. Phosphatidylinositol 3-kinase, a novel target molecule for the inhibitory effects of kaempferol on neoplastic celltransformation. Carcinogenesis, 2010, 31, 1338-1343.
93. Lee, K.M.; Lee, K.W.; Jung, S.K.; Lee, E.J.; Heo, Y.; Lee, H.J.; Dong, Z. Kaempferol inhibits UVB-induced COX-2 expression bysuppressing Src kinase activity. Biochem. Pharmacol., 2010, 80,2042-2049.
94. Schwartzberg, P.L.; The many faces of Src: multiple functions of aprototypical tyrosine kinase. Oncogene, 1998, 17, 1463-1468.
95. Johnson, J.L.; Rupasinghe, S.G; Stefani, F.; Schuler, M.A.; Mejia, E.G.; Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3b enzymatic activity by lowering the in-teraction energy within the binding cavity. J. Med. Food., 2011, 14,325-333.
96. Patil, J.; Jayaprakasha, G.; Murthy, K.; Chetti, M.; Patil, B.; Characterization of Citrus aurantifolia bioactive compounds and theirinhibition of pancreatic cancer cells through apoptosis. Microchem.J., 2010, 94, 108-117.
97. Dong, X.; Zhou, X.; Jing, H.; Chen, J.; Liu, T.; Yang, B.; He, Q.; Hu, Y.; Pharmacophore identification, virtual screening and bio-logical evaluation of prenylated flavonoids derivatives asPKB/Akt1 inhibitors. Eur. J. Med. Chem., 2011, 46, 5949-5958.
98. Sourbier, C.; Lindner, V.; Lang, H.; Agouni, A.; Schordan, E.; Danilin, S.; Rothhut, S.; Jacqmin, D.; Helwig, J.; Massfelder, T. The phosphoinositide 3-kinase/Akt pathway: a new target in humanrenal cell carcinoma therapy. Cancer Res., 2006, 66, 5130-5142.
99. Venkatachalam, C.M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit: a novel method for the shape-directed rapid docking ofligands to protein active sites. J. Mol. Graphics Model., 2003, 21,289-307.
100. Rao, S.N.; Head, M.S.; Kulkarni, A.; LaLonde, J.M. ValidationStudies of the Site-Directed Docking Program LibDock. J. Chem.Inf. Model., 2007, 47, 2159-2171.
101. Garrett, M.A. Cell cycle control and cancer. Curr. Sci., 2001, 81,515-522.
102. Khuntawee, W.; Rungrotmongkol, T.; Hannongbua, T. Moleculardynamic behavior and binding affinity of flavonoid analogues tothe cyclin dependent kinase 6/cyclin D complex. J. Chem. Inf.Model., 2012, 52, 76 83.
103. Chen, H.; Yao K.; Nadas J.; Bode A.M.; Malakhova, M.; NaomiOi, N.; Li, H.; Lubet R.A.; Dong, Z. Prediction of molecular targetsof cancer preventing flavonoid compounds using computationalmethods. PLoS One., 2012, 7, e38261
104. Ciocca, D.R.; Calderwood, S.K. Heat shock proteins in cancer:diagnostic, prognostic, predictive, and treatment implications. CellStress Chaperon., 2005, 10, 86-103.
105. Chen, C.Y.; Chen, G.; Chen W.Y. Molecular Simulation ofHER2/neu Degradation by Inhibiting HSP90. J. Chin. Chem. Soc-Taip., 2008, 55, 297-302.
106. Lee J.; Jung, K.; Kim, Y. inhibitor design for human heat shockprotein 70 ATPase domain by pharmacophore-based in silicoscreening. Bull. Korean Chem. Soc., 2008, 29, 1717-1722.
107. Deschamps, J.D.; Kenyon, V.A.; Holman, T.R. Baicalein is a po-tent in vitro inhibitor against both reticulocyte 15-human and plate-let 12-human lipoxygenases. Bioorg. Med. Chem., 2006, 14, 4295-4301.
108. Steele, V.E.; Holmes, C.A.; Hawk, E.T.; Kopelovich, L.; Lubet, R.A.; Crowell, J.A.; Sigman, C.C.; Kellof, G.J. Cancer Epidemiol.Biomarkers Prev., 1999, 8, 467-483.
109. Takasawa, R.; Takahashi, S.; Saeki, K.; Sunaga, S.; Yoshimori, A.; Tanuma, S. Structure-activity relationship of human GLO I inhibi-tory natural flavonoids and their growth inhibitory effects. Bioorg.Med. Chem., 2008, 16, 3969-3975.
110. Cai H.; Sale S.; Schmid, R.; Britton R.G.; Brown, K.; Steward, W.P.; Gescher, A.J.; Flavones as Colorectal Cancer Chemopreven-tive Agents—Phenol-OMethylation Enhances Efficacy. CancerPrev. Res., 2009, 2, 743-750.
111. Lee, J.; Kim, J.; Cho, M.; Shin, S.; Yoon, D.; Heo, Y.S.; Kim Y.; Cytotoxic Flavonoids as Agonists of Peroxisome Proliferator-Activated Receptor on Human Cervical and Prostate CancerCells. J. Nat. Prod., 2010, 73, 1261-1265.
112. Lee, J.; Kim, J.; Lee, S.; Lee, E.; Shin, S.; Jin, Q.; Yoon, D.; Woo,E.; Kim Y.; Binding model of amentoflavone to peroxisome prolif-erator-activated receptor. Bull. Korean Chem. Soc., 2012, 33,1475-1479.
113. Maliepaard, M.; van Gastelen, M.A.; de Jong, L.A.; Pluim, D.; vanWaardenburg, R.C.; Ruevekamp-Helmers, M.C.; Floot, B.G.; Schellens, J.H. Overexpression of the BCRP/MXR/ABCP gene in atopotecan-selected ovarian tumor cell line. Cancer Res., 1999, 59,4559-4563.
114. Boumendjel, A.; Di Pietro A.; Dumontet, C.; Barron, D. Recentadvances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein.responsible for cancer cellmultidrug resistance. Med. Res. Rev., 2002, 22, 512-529.
115. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a La-marckian genetic algorithm and an empirical binding free energyfunction. J. Comput. Chem., 1998, 19, 1639-1662.
116. Ehrman, T.M.; Barlow, D.J.; Hylands, P.J. In silico search formulti-target anti-inflammatories in Chinese herbs and formulas. Bioorg. Med. Chem., 2010, 18, 2204-2218.
117. Manning, A. M.; Davis, R. J. Targeting JNK for therapeutic bene-fit: from junk to gold? Nat. Rev. Drug Disc., 2003, 2, 554-565.
118. Phosrithong, N.; Ungwitayatorn, J. Molecular docking study onanticancer activity of plant-derived natural products. Med. Chem.Res., 2010, 19, 817-835.
119. Gacche, R.N.; Shegokar, H.D.; Gond, D.S.; Yang, Z.; Jadhav, A.D. Evaluation of selected flavonoids as antiangiogenic, anticancer, andradical scavenging agents: an experimental and in silico analysis.Cell Biochem. Biophys., 2011, 61, 651-663
120. Zhong, H.; De Marzo, A.M.; Laughner, E.; Lim, M.; Hilton, D.A.; Zagzag, D.; Buechler, P.; Isaacs, W.B.; Semenza, G.L.; Simons, J.W. Overexpression of hypoxia-inducible factor-1 alpha in com-mon human cancers and their metastases. Cancer Res., 1999, 59,5830-5835.
121. Vina, D.; Uriarte, E.; Orallo, F.; Gonzalez-Diaz, H. Alignment-freeprediction of a drug-target complex network based on parametersof drug connectivity and protein sequence of receptors. Mol.Pharm., 2009, 6, 825-835.
122. Speck-Planche, A.; Luan, F.; Cordeiro, M.N. Role of ligand-baseddrug design methodologies toward the discovery of new anti-Alzheimer agents: futures perspectives in Fragment-Based LigandDesign. Curr. Med. Chem., 2012, 19, 1635-1645.
123. Speck-Planche, A.; Kleandrova, V.V.; Scotti, M.T. Fragment-basedapproach for the in silico discovery of multi-target insecticides.Chemometr. Intell. Lab. Syst., 2012, 111, 39-45.
124. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Predicting multiple ecotoxicological profiles in agrochemicalfungicides: a multi-species chemoinformatic approach. Ecotoxicol.Environ. Saf., 2012, 80, 308-313.
125. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Aligand-based approach for the in silico discovery of multi-targetinhibitors for proteins associated with HIV infection. Mol. Biosyst.,2012, 8, 2188-2196.
126. Speck-Planche, A.; Kleandrova, V.V. In silico design of multi-target inhibitors for C-C chemokine receptors using substructuraldescriptors. Mol. Divers., 2012, 16, 183-191.
127. Speck-Planche, A.; Kleandrova, V.V.; Rojas-Vargas, J.A. QSARmodel toward the rational design of new agrochemical fungicideswith a defined resistance risk using substructural descriptors. Mol.Divers., 2011, 15, 901-909.
128. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Multi-target drug discovery in anti-cancer therapy: fragment-based approach toward the design of potent and versatile anti-prostate cancer agents. Bioorg. Med. Chem., 2011, 19, 6239-6244.
129. Tenorio-Borroto, E.; Penuelas Rivas, C.G.; Vasquez Chagoyan, J.C.; Castanedo, N.; Prado-Prado, F.J.; Garcia-Mera, X.; Gonzalez-Diaz, H. ANN multiplexing model of drugs effect on macrophages;theoretical and flow cytometry study on the cytotoxicity of the anti-microbial drug G1 in spleen. Bioorg. Med. Chem., 2012, 20, 6181-6194.
130. Prado-Prado, F.J.; Garcia-Mera, X.; Gonzalez-Diaz, H. Multi-targetspectral moment QSAR versus ANN for antiparasitic drugs againstdifferent parasite species. Bioorg. Med. Chem., 2010, 18, 2225-2231.
131. Perez-Montoto, L.G.; Santana, L.; Gonzalez-Diaz, H. Scoringfunction for DNA-drug docking of anticancer and antiparasiticcompounds based on spectral moments of 2D lattice graphs formolecular dynamics trajectories. Eur. J. Med. Chem., 2009, 44,4461-4469.
132. Prado-Prado, F.J.; Gonzalez-Diaz, H.; de la Vega, O.M.; Ubeira, F.M.; Chou, K.C. Unified QSAR approach to antimicrobials. Part3: first multi-tasking QSAR model for input-coded prediction,structural back-projection, and complex networks clustering ofantiprotozoal compounds. Bioorg. Med. Chem., 2008, 16, 5871-5880.
133. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Insilico discovery and virtual screening of multi-target inhibitors forproteins in Mycobacterium tuberculosis. Comb. Chem. HighThroughput Screen., 2012, 15, 666-673.
134. Speck-Planche, A.; Cordeiro, M.N.D.S. Application ofBioinformatics for the search of novel anti-viral therapies: Rationaldesign of anti-herpes agents. Curr. Bioinform., 2011, 6, 81-93.
135. Prado-Prado, F.; Garcia-Mera, X.; Abeijon, P.; Alonso, N.; Caamano, O.; Yanez, M.; Garate, T.; Mezo, M.; Gonzalez-Warleta, M.; Muino, L.; Ubeira, F.M.; Gonzalez-Diaz, H. Using entropy ofdrug and protein graphs to predict FDA drug-target network:theoretic-experimental study of MAO inhibitors and hemoglobinpeptides from Fasciola hepatica. Eur. J. Med. Chem., 2011, 46,1074-1094.
136. Prado-Prado, F.J.; Ubeira, F.M.; Borges, F.; Gonzalez-Diaz, H. Unified QSAR & network-based computational chemistryapproach to antimicrobials. II. Multiple distance and triadic censusanalysis of antiparasitic drugs complex networks. J. Comput.Chem., 2009, 31, 164-173.